Please assess the completion status of the following clinical trial:

Trial Title: Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥18 years with advanced or metastatic solid tumor not amenable to any clinical improvement by current standard treatments and suitable for a treatment with cisplatin~  * Life expectancy more than 3 months~ * ECOG Performance status 0-1~ * Absence of any conditions in which hypervolemia and its consequences (e.g. increased stroke volume, elevated blood pressure) may represent a risk for the patient~ * Adequate baseline bone marrow, hepatic and renal function, defined as follows:~ * Neutrophils \> 1.5 x 10\^9/L and platelets \> 100 x 10\^9/L~ * Bilirubin \< 1.5 x ULN~ * AST and/or ALT \< 2.5 x ULN in absence of liver metastasis~ * AST and/or ALT \< 5 x ULN in presence of liver metastasis~ * Serum creatinine \< 1.5 x ULN~ * Creatinine clearance (estimated according to Cockcroft-Gault formula) ≥ 50 ml/min~ * Patients may have had prior therapy providing the following conditions are met:~* Chemotherapy, radiation therapy, hormonal therapy or immunotherapy: wash-out period of 28 days~* Corticosteroid therapy wash out period of 14 days~* Surgery: wash-out period of 14 days~* Patients must give written informed consent to participate in the study~Exclusion Criteria:~* Previous signs of severe toxicity platinum related~* Patients must not receive any other investigational agents while on study~* New York Heart Association class III or IV cardiac disease~* Unstable angina~* Patients with myocardial infarction within the last six (6) months~* Patient with significant peripheral vascular disease~* Clinical signs of CNS involvement~* Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol~* Known hypersensitivity/allergic reaction to human albumin preparations or to any of the excipients~* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol~* Pregnancy or lactation. Patients - both males and females - with reproductive potential (i.e. menopausal for less than 1-year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).